Beijing Hotgen Biotech Co Ltd (688068) — Capital Reinvestment Ratio
Beijing Hotgen Biotech Co Ltd (688068) has a Capital Reinvestment Ratio of 4.82x as of September 2025, meaning it reinvests 5% of its operating cash flow (CN¥3.05 Million) in capital expenditures (CN¥14.73 Million). See 688068 net asset quality score to measure how much of total assets are equity-financed.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Beijing Hotgen Biotech Co Ltd Capital Reinvestment Ratio (2016–2022)
This chart tracks Beijing Hotgen Biotech Co Ltd's Capital Reinvestment Ratio across 7 annual periods. Check 688068 capex plus investments ratio to assess the company's total reinvestment commitment from operating cash flow.
Annual Capital Reinvestment Ratio for Beijing Hotgen Biotech Co Ltd (2016–2022)
Year-by-year Capital Reinvestment Ratio for Beijing Hotgen Biotech Co Ltd from 2016 to 2022. For live market cap and broader valuation context, see 688068 market cap overview.
| Year | Reinvestment Ratio | Operating CF (CNY) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2022 | 0.58x | CN¥978.75 Million | CN¥565.21 Million | ▲ +282.9% |
| 2021 | 0.15x | CN¥2.64 Billion | CN¥398.86 Million | ▼ -85.6% |
| 2020 | 1.05x | CN¥164.62 Million | CN¥172.27 Million | ▼ -77.1% |
| 2019 | 4.57x | CN¥19.37 Million | CN¥88.48 Million | ▲ +498.5% |
| 2018 | 0.76x | CN¥55.04 Million | CN¥42.00 Million | ▼ -74.6% |
| 2017 | 3.01x | CN¥22.95 Million | CN¥69.05 Million | ▲ +546.9% |
| 2016 | 0.47x | CN¥45.54 Million | CN¥21.18 Million | — |